CPRX
Catalyst Pharmaceuticals Partners, Inc.
Data as of 2026-07-21
Company attributes
Price
Interactive 5-year price history chart for CPRX. Latest close $31.49.
Pillar breakdown
0–100 percentile rank against the current universe (sector-relative for Quality / Value / Growth / Profitability)
- QualityProfit margins & asset efficiency81ExceptionalHealth Care median (n=166) 50
- ValuePrice vs fundamentals64StrongHealth Care median (n=166) 52
- GrowthRevenue & earnings trajectory86ExceptionalHealth Care median (n=166) 50
- MomentumRecent price strength87ExceptionalHealth Care median (n=166) 49
- HealthBalance sheet & solvency79ExceptionalHealth Care median (n=166) 57
- ProfitabilityROE, ROA, ROIC84ExceptionalHealth Care median (n=166) 48
- TechnicalTrend & volatility signals65StrongHealth Care median (n=166) 56
- RiskVolatility & drawdown profile69StrongHealth Care median (n=166) 46
Pillars not shown: Sentiment, ML (Phase 5+).
Risk Summary
1 active- Sloan accruals — top decile[sloan_accruals_top_decile]Within-sector top decile of accruals / assets (Sloan 1996).
These flags keep the raw composite rank (project Rule 16) but forfeit the entered_top5 badge. Two of them — altman_distress and data_quality_input_corruption — additionally force a cautious recommendation; the others act as Top-5 disqualifiers without dictating the buy/hold/sell label on their own.
- Restatement history (10-K/A, 5y)[restatement_history]
- Accruals momentum (Δ TATA > 0.05 over 3y)[accruals_momentum_high]
- Insider sell cluster (Cohen-Malloy-Pomorski 2012)[insider_sell_cluster]
- C-suite unusual selling (Jeng-Metrick-Zeckhauser 2003)[c_suite_unusual_sell]
Rolls up Phase 4.5 earnings-manipulation defenses (Sloan · Beneish · Dechow · REM · restatement · late-filing · earnings- quality time-series) into a single 0-100 risk index. The soft composite penalty (max 10 pts) is informational only — the ranking uses the raw composite score per project Rule 16.
Fair price check
6 different valuation methods each estimate what CPRXshould be worth, then we compare to today's price.
- EV/EBITDAUndervaluedthinks it's a bargain — estimates $56.25, about 79% above today
- P/B multiplesUndervaluedthinks it's a bargain — estimates $43.72, about 39% above today
- P/E multiplesUndervaluedthinks it's a bargain — estimates $42.68, about 36% above today
- DCF (2-stage)Overvaluedthinks it's expensive — estimates $21.32, about 32% below today
- Graham (defensive)Overvaluedthinks it's expensive — estimates $14.06, about 55% below today
- Residual IncomeOvervaluedthinks it's expensive — estimates $11.52, about 63% below today
How to read this: “Cheap” = method's fair price is at least 20% above today. “Fair” = within ±10–20%. “Pricey” = at least 10% below today. Outliers (values more than 5× or less than 0.2× today's price) are excluded.
Fair price ensemble
- Median fair
- $32.00
- Margin of safety(vs fair value)
- +1.6%
- Max (ex-outliers)
- $56.25
- Tangible BVPS
- $7.28
- Restatement history
- Accruals momentum
- Insider-sell cluster
- C-suite unusual selling
Median of all applicable methods (current price $31.49). Per-method estimates + each method’s cheap/fair/pricey read are in the Fair price check above. Outliers above 5× or below 0.2× current price are excluded from the max but kept in the median. See methodology for the 6-method ensemble + 7 defenses.
Defense layer. Flags mark elevated risk, never confirmed fraud. This model cannot catch every manipulation and decays after publication — weigh it against its stated error rates.
Supporting dataRaw fundamentals & data-quality provenance behind the scores above
Raw fundamentals (SEC EDGAR)
| Metric | Value |
|---|---|
| Market cap | $3.85B |
| Revenue (TTM) | $596.96M |
| Net income (TTM) | $221.32M |
| Operating cash flow (TTM) | $208.21M |
| CapEx (TTM) | $85.00K |
| Free cash flow (TTM)CFO − CapEx | $208.13M |
| Total assets | $1.15B |
| Total liabilities | $134.91M |
| Stockholders' equity | $1.01B |
| Cash & equivalents | $755.86M |
| Shares outstanding | 122.38M |
| EPS (basic) | $1.81 |
| EPS (diluted) | $1.81 |
| P/E ratio (TTM) | 17.41 |
TTM = trailing twelve months. Balance sheet items are point-in-time (latest filing).
Data quality
- Latest filed date
- 2026-05-11
- Latest period end
- 2026-05-07
- Filing lag
- 71 days
- Missing metrics
- 6(gross_profit, interest_expense, dividends_paid, long_term_debt, short_term_debt, goodwill)
Composite is the 8-pillar weighted score over quality, value, growth, momentum, health, profitability, technical, and risk. Sentiment + ML pillars are reserved for a later phase; until then their weight redistributes pro-rata. Fair price is the median of 6 valuation methods (Graham, P/E / P/B / EV-EBITDA multiples, RIM, DCF) with outliers above 5× current price excluded from the max. Risk-overlay flags annotate only — they suppress the entered-top-5 badge but do not modify the composite.